---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-002945"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:16:57.177509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma reaches 25% enrollment in Phase 2 trial of Ropidoxuridine for glioblastoma

## Summary
- Initial randomization targets 40 patients: 20 at 1,200 mg/day, 20 at 960 mg/day to identify optimal dose.
- After optimal dose selected, 14 more patients will be enrolled for survival comparison vs. historical controls.
- Trial focuses on IDH wild-type, methylation-negative glioblastoma; standard care is radiation only.
- Ropidoxuridine previously received FDA Orphan Drug Designation; six major cancer centers are participating.
- CEO Anatoly Dritschilo said enrollment is ahead of expectations; no results or guidance changes reported.

## SEC filing metadata
- accession: 0001493152-25-002945
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225002945/0001493152-25-002945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225002945/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-002945
- JSON: https://secwatch.observer/filing/0001493152-25-002945.json
- Plain text: https://secwatch.observer/filing/0001493152-25-002945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.